Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 22, 2018

Primary Completion Date

November 28, 2018

Study Completion Date

November 28, 2018

Conditions

Bioequivalence

Interventions

DRUG

RID-TDS 9.5 mg/24 h

3 consecutive applications of 1 patch (1st patch for 4 days, 2nd patch for 3 days, 3rd patch for 4 days) covering an 11-day period

DRUG

Exelon® 9.5 mg/24 h

11 consecutive applications of 1 patch (each patch will be applied for 1 day) covering an 11-day period

Trial Locations (1)

SocraTec R&D GmbH, Clinical Pharmacology Unit, Erfurt

All Listed Sponsors

collaborator

SocraMetrics GmbH

INDUSTRY

lead

SocraTec R&D GmbH

OTHER

NCT03659435 - Rivastigmine Bioequivalence Trial With Multiple Application of Transdermal Patches (9.5mg/24h) | Biotech Hunter | Biotech Hunter